Fludarabine combined with pirarubicin chemotherapy for patients with relapsed or refractory indolent non-Hodgldn lymphoma

( views:, downloads: )
Author:
WANG Hua-qing(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
HAO Xi-shan(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
QIU Li-hua(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
QIAN Zheng-zi(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
LI Wei(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
MENG Xing-rui(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
HOU Yun(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
SONG Zheng(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
ZHAO Jing(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
CUI Xiu-zhen(Department of Lymphoma, Tianjin Medical University Cancer Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China)
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 18, Issue 10, 2009
DOI:
10.3760/cma.j.issn.1009-9921.2009,10.010
Key Word:
Lymphoma, non-Hodgkin; Fludarabine; Piranubicin

Abstract: Objective To evaluate the efficacy and safety of fludarabine and pirarubicin (FT) regimen in the treatment of refractory or relapsed indolent non-Hodgkin lymphoma (NHL). Methods A total of 40 patients with relapsed or refractory indolent NHL were treated with FT regimen, one cycle for 28 days, total 6 cycles. The data of indolent NHL patients treated with fludarabine, noventrene and dexamethasone (FND) regimen were collected as control. Results 40 patients were given 228 cycles chemotherapy, overall response rate was 62.5 %, median progression-free survival was more than 20 months and 2 years overall survival rate was 70.0 %. The main toxicities was leucopenia (80.0 %), but the incidence of WHO Ⅲ-Ⅳ leucopenia and pneumonia was less than that of in the control group, the rate were 12.5 % vs 29.0 % and 2.5 % vs 23.0 % respectively (P <0.05). Conclusion The efficacy of FT regimen was as good as FND regimen, but the incidence of leucopenia and pneumonia by Ⅲ-Ⅳ was lower in FT group than in FND group. So the FT regimen was an effective and safe second-line salvage regimen for relapsed or refractory indolent non-Hodgkin lymphoma.

  • [1]王华庆.惰性淋巴瘤治疗的新模式及思考.中国医刊,2007,42:25-27.
  • [2]冯建军,杨林花,陈剑芳,等.R-CHOP方案对低中恶性B细胞非霍奇金淋巴瘤疗效及不良反应的Meta分析.白血病·淋巴瘤,2009,18:216-219.
  • [3]Ghielmini M,Schmitz S,Cogliatti S,et al.Prolonged treatment with 2-monthly rituximab signlficanfly improves event free survival and duration of response in patients with follicular lyraphoma:a randomized SAKK trial.Blood,2002,100:161A.
  • [4]Foussard C,Colombat P,Maisonneuve H,et al.Long-term follow-up of a randomized trial of fludarabine-mitoxantrone,compared with cyclophosphamide,doxorubicin,vindesine,prednisone (CHVP),as first-line treatment of elderly patients with advanced,low-grade non-Hodgkin/s lymphoma before the era of moncolonal antibodies.Ann Oncol,2005,16:466-472.
  • [5]Zinzani PL,Pulsoni A,Perrotti A,et al.Fludarabine plus mitoxantrone with and without Rituximab versus CHOP with and without Rituximab as front-line treatment for patients with follicular lymphoma.J Clin Oncol,2004,22:1-8.
  • [6]Zinzani PL,Magagnoli M,Bendandi M,et al.Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin lymphoma.Ann Oncol,2000,11:363-365.
  • [7]Bordonaro R,Petralia G,Restuccia N,et al.Fludarabine,mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed,low-grade non-Hodgkin lymphomas with unfavorable prognostic factors:results of a phase Ⅱ study.Leuk Lymphoma,2004,45:93-100.
  • [8]Mclaughlin P,Hagemeister FB,Romaguera JE,et al.Fludarabine,mitoxantrone,and dexamethasone:an effective new regimen for indolent lymphnma.J Clin Oncol,1996,14:1262-1268.
  • [9]Crawly CR,Foran JM,Gupta RK,et al.A phase Ⅱ study to evaluate the combination of fludarabine,mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.Ann Oncol,2000,11:861-865.
  • [10]Ma SY,Au WY,Chim CS,et al.Fludarabine,mitoxantrone and dexamethasone in the treatment of indolent B-and T-cell lymphoid malignancies in Chinese patients.Br J Haematol,2004,124:754-761.
  • [11]刘艳艳,杨树军,李玉富,等.吡柔比星联合COP叫周方案治疗侵袭性非霍奇金淋巴瘤骨髓浸润.白血病·淋巴瘤,2009,18:163-165.
  • [12]Kano Y,Akutsu M,Tsunoda S,et al.In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.Leukemia,2000,14:379-388.
  • [13]Gandhi V,Plunkett W.Cellular and clinical pharmacology of fludarabine.Clin Pharmacokinet,2002,41:93-103.
  • [14]Hendry L,Bowen A,Matutes E,et al.Fludarabine,cyclophosphamide and mitoxantrone in relapse or refractory chronic lymphocytic leukemia and low grade non-Hodgkin lymphoma.Leuk Lymphoma,2004,45:945-990.
  • [15]William SV,Danika L,Thomas MG,et al.Combination of fludarabine and mitoxantrone in untreated stage Ⅲ and Ⅳ low-grade lymphoma:S9501.J Oncol,2003,21:1996-2003.
  • [16]Hochster HS,Oken MM,Winter JN,et al.Phase I studies of fludarabine plus cycluphosphamide in patients with previously untreated low-grade lymphoma:results and long-term follow-up-a report from the eastern cooperative oncology group.J Clin Oncol,2000,18:987-994.
  • [17]Tsimberidou AM,Mclanghlin P,Younes A,et al.Fludarabine,mitoxantrone,dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage Ⅳ indolent lymphoma.Blood,2002,100:4351--4357.
  • [18]周水阳,钱樱,陈钰,等.氟达拉滨为主方案治疗复发难治性惰性非霍奇金淋巴瘤20例.白血病·淋巴瘤,2008,17:65-67.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn